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ABSTRACT – The affective disorders programme at the University of Barcelona Hospital
Clinic involves two separate subgroups according to their research target: the Unipolar
Depression subgroup and the Barcelona Bipolar Disorders Programme. Both are part of
the Spanish “Centro de Investigación Biomédica En Red en Salud Mental” (CIBERSAM),
which is a Virtual Center of Network Research in Mental Health and Psychiatry, which
has gathered the best research groups in Psychiatry and related disciplines in Spain. The
Clinic-Affective Disorders research group has focused on the neurobiology (genetics, bio-
markers, neuropsychology, neuroimaging), epidemiology (clinical subtypes, comorbidity,
psychometric assessment, functionality), and treatment of bipolar and unipolar affective
disorders (including pharmacological, biophysical, and psychosocial strategies). It has an
outstanding and long tradition of collaborative research with national and international
groups, and publishes over 60 original articles per year based on research findings, many
of which have had significant impact on clinical practice.
Received 31 December 2008
Revised 12 March 2009
Accepted 12 March 2009
The CIBERSAM and the
precedents
The birth, since 2008, of the Spanish
“Centro de Investigación Biomédica En Red
en Salud Mental” (CIBERSAM), which is a
Virtual Center of Network Research in
Mental Health and Psychiatry, was a corner-
stone in the history of Spanish research in
mental disorders. The CIBERSAM has en-
hanced quite substantially the productivity
of the best research groups in Psychiatry and
related disciplines, most of which had al-
ready been funded in 2007 by the Instituto de
Salud Carlos III through the Red de
trastornos afectivos y psicóticos (REM-TAP)
and a few other networks on neurologic dis-
eases, child psychosis, epidemiology, genet-
ics, and consultation psychiatry. In the past,
psychiatry research in Spain was very much
dependent on individual action from specific
research groups, which would look for fund-
ing from the Spanish Fondo de Investigación
Sanitaria (FIS), foreign institutions (such as
the Stanley Foundation), and the pharmaceu-
tical industry. This fact, combined with the
dearth of actual investment, had a negative
impact on the strategy of the groups that were
struggling to do high-quality research on a
long-term basis. The CIBERSAM was born
as a new era in Mental Health research in
Spain, providing unprecedented long-term
funding to the best research groups and en-
hancing translational, collaborative research
across the country. Moreover, all the process
was made under the highest transparency,
fair competition, and peer-review.
The affective disorders programme at the
University of Barcelona Hospital Clinic
which I have the honour to coordinate in-
volves two separate subgroups according to
their research target: the Unipolar Depres-
sion subgroup and the Barcelona Bipolar
Disorders Programme. 
The Unipolar Depression
Subgroup
This subgroup is leaded by Cristóbal
Gastó, Chair of Psychiatry at the University
of Barcelona, and includes Jordi Blanch,
Teodor Marcos, Víctor Navarro, and recently
Rocío Martín-Santos. They have been ex-
tremely succesful in investigating genetic
polymorphisms and their relationship to
therapeutic response1, the role of serotoner-
gic receptors in depression and its treat-
ment2, the specific issues related to depres-
sion in the elderly3, and cognition4. The
group is involved in several CIBERSAM-
funded multicenter projects, such as the DE-
PRES study, and collaborates on a long-
term basis with other CIBERSAM groups
such as the one leaded by Lourdes Fañanás.
The Bipolar Disorder Subgroup
This subgroup involves most members of
the Barcelona Bipolar Disorder Programme
at the University of Barcelona Hospital Clin-
ic (BDP). The BDP integrates clinical care,
education, research and management devot-
ed to provide excellence in care and knowl-
edge on bipolar disorder, and it belongs to 3
institutions: the Hospital Clinic, the Universi-
ty of Barcelona, and the Institut d’Investigació
Biomédica August Pi i Sunyer, (IDIBAPS). 
The functional unit that provides clinical
care to patients with bipolar disorder is the Bipo-
lar Disorder Unit at the Hospital Clinic, which
delivers specialized care to bipolar patients at-
tending the hospital regardless of their condition
as in-or out-patients. Bipolar outpatients may
come for specialized secondary care (Mental
Health Center) or for tertiary care as reference
center for particularly difficult-to-treat cases. I
am the director of the Programme and I coordi-
nate a large multidisciplinary team, which in-
volves excellent mental health professionals and
researchers such as Antoni Benabarre, Mar
Bonnín, Francesc Colom, Mercè Comes, Núria
Cruz, Claire Daban, Carolina Franco, José
Manuel Goikolea, Anabel Martínez-Arán, Is-
abella Pacchiarotti, María Reinares, Adriane
Rosa, José Sánchez-Moreno, Carla Torrent,
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and Marc Valentí. Several professionals col-
laborate with the team, including young in-
vestigators, fellows and residents, such as
Piero Castro, Andrea Murru, Lorenzo Maz-
zarini, Alessandra Nívoli and Ekaterina
Popova, among other.
The BDP research has focused on the neuro-
biology (genetics, biomarkers, neuropsycholo-
gy, neuroimaging), epidemiology (clinical sub-
types, comorbidity, psychometric assessment,
functionality), and treatment of bipolar illness
(including pharmacological, biophysical, and
psychosocial strategies). It has an outstanding
and long tradition of collaborative research
with national and international groups, depart-
ing from the premise that true science has no
geographical or cultural borders, and that little
can be done separately. The CIBERSAM has
provided further impulse to collaborative pro-
jects, yielding a growing number of multi-au-
thored scientific publications involving two or
even more groups within the CIBERSAM and
beyond. Special mention is deserved for the
long-standing collaboration with the CIBER-
SAM’s Valencia-Alicante group (leaded by
Rafael Tabarés), Vitoria (Ana González-
Pinto), Madrid (José Luís Ayuso), Sant Joan de
Déu (Josep María Haro), and several more that
are currently ongoing.
Some of the most relevant BDP output in
2008, just after one year since the start of the
CIBERSAM, include, in the neurobiological
arena: the development of a model of allostat-
ic load for bipolar disorder5, the replication of
genetic findings involving specific mutations
in bipolar disorder and schizophrenia6, cross-
sectional7-9 and longitudinal10-12 neurocogni-
tive studies indicating long-term persistence
of cognitive deficits, even during remission,
and innovation in brain neuroimaging quan-
tification techniques13. In the area of epidemi-
ology, our group has developed strategies to
improve the screening and early detection of
bipolar disorder in depressed patients, the as-
sessment of subclinical symptoms15 and de-
pression subtypes16, and comorbidity17-18; fur-
thermore, we have conducted studies on psy-
chosocial adjustment and functional
outcome19 and innovative proposals related to
the forthcoming classifications of mental dis-
orders, such as the DSM-V20-22. Innovation
has been further fostered through the develop-
ment, adaptation, and validation of several
psychometric tools aimed at diagnostic screen-
ing23, neuropsychological assessment24, sever-
ity rating25, and evaluation of comorbidity26.
Our group has been particularly active in the
publication of international consensus docu-
ments for the diagnosis, cognitive assess-
ment, follow-up and treatment of people with
bipolar disorder27-33. Finally, in 2008 our
group has made important contributions to
the progress in the treatment of bipolar disor-
der34-41, including a better knowledge of the
efficacy and safety profile of traditional thera-
pies such as lithium42, and modern strategies
such as the use of long-acting injectable
risperidone in difficult-to-treat and poorly ad-
herent patients43. Several pivotal randomized
clinical trials were conducted and published
this year, allowing the registration of new in-
dications for drugs as aripiprazole44, quetiap-
ine45,46, and ziprasidone47, and several more,
not necessarily sponsored by the pharmaceu-
tical industry, provided relevant input on the
potential role of oxcarbazepine48 and amisul-
pride49; a third group of trials has yielded
substantial information on treatment response
in specific clinical subgroups50-51. The BDP
priorizes research upcoming from the clinical
arena, and although basic and translational
research are seen as crucial, and methodology
is given the greatest attention, observational
studies are considered highly valuable as
well52-56. Such studies lack the rigour of
placebo-controlled, randomized trials, but
they have greater external validity and eco-
logical value. One of them is the European
study called EMBLEM. The contribution of
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the BDP to bipolar therapeutics is not limited
to pharmacological treatment, but actually in-
volves a great deal of psychotherapy research,
including the empirical testing of innovative
approaches such as group psychoeducation,
(with the first report on psychoeducation for
bipolar II disorder)57, family psychoeduca-
tion58, and biophysical treatments, such as
vagus nerve stimulation59 and the traditional
electroconvulsive therapy60. Our group has
also made relevant contributions to research
methodology61,62. 
Ongoing and future projects
The main output from the Affective Disor-
ders Program at the University of Barcelona
Hospital Clinic after the birth of the CIBER-
SAM has been summarized in the preceding
pages, but there is evidently a great deal of
ongoing research that may yield further pub-
lications, patents and innovation within the
forthcoming years. Some of those involve a
large, multicenter study on first-episode psy-
chosis (including affective psychoses), the
clinical trial on treatment-resistant unipolar
depression named DEPRES, a large, innova-
tive, multicenter trial involving 10 groups
from the CIBERSAM on the efficacy of cog-
nitive rehabilitation in bipolar disorder, a
translational study on molecular biomarkers
in collaboration with the Vitoria group, and
several psychometric projects on the validity
of the Functioning Assessment Short Test
(FAST) subscales and the predictive validity
for weight gain of the Barcelona Bipolar Eat-
ing Disorder Scale (BEDS). Among the non-
collaborative projects, there is one on indi-
vidual neurocognitive rehabilitation (funded
by the Fondo de Investigación Sanitaria with
Anabel Martínez-Arán as principal investi-
gator), another one on biomarkers for treat-
ment response to psychoeducation, leaded by
Francesc Colom, a third one on genetic poly-
morphisms and lithium response by Antoni
Benabarre, and another one on long-term effi-
cacy of electroconvulsive therapy, by José
Manuel Goikolea, among other. The recent fi-
nalization of a large FIS project, linked to the
European study named MHADIE, in cooper-
ation with the group from the Hospital de La
Princesa in Madrid, may produce a large
number of publications in the nearest future.
Moreover, international collaboration may be
substantially fostered by means of the EN-
BREC project, of which I am the principal in-
vestigator in Spain. The ENBREC (European
Network of Bipolar Expert Centres) is a 7th-
Framework-European-Programme funded
project that aims at developing networks of
networks for bipolar disorder research in Eu-
rope. The ENBREC project has also received
funding and support from the European Col-
lege of Neuropsychopharmacology (ECNP).
Conclusions
The Affective Disorders Program at the
University of Barcelona Hospital Clinic is
one of the most active and productive teams
of the CIBERSAM and conducts high-quality
research in the fields of unipolar depression
and bipolar disorder with a strong collabora-
tive, multidisciplinary, translational, and in-
novative emphasis. During the short period of
a year since the birth of the CIBERSAM it
has been already able to generate over 60
high-impact publications and over 1 million
Euro additional funding. This is a tangible
and unequivocal proof of the success of the
CIBERSAM and of the quality and produc-
tivity of Spanish Psychiatry when enough
funding and resources are provided. In the
near future, the CIBERSAM may expand its
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research activity and networking over Europe
through networks of networks, fostering its
capacity to develop further large, multisite
collaborative international projects for a bet-
ter use of research resources beyond local
policies, as proven by the ENBREC project in
the specific case of bipolar disorder. Hopeful-
ly this will be a foundational item in the agen-
da of decision-makers on European and inter-
national research on Mental Health. 
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